Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.

ABSTRACT:

Objectives

Patients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in three epidemiological settings.

Design

Cost-effectiveness analysis using Markov cohort model.

Setting

South Africa, Georgia and the Philippines.

Participants

XDR-TB and multidrug-resistant tuberculosis (MDR-TB) failure and treatment intolerant patients.

Interventions

BPaL regimen. PRIMARY AND SECONDARY OUTCOME MEASURES: (1) Incremental cost per disability-adjusted life years averted by using BPaL against standard of care

SUBMITTER: Gomez GB 

PROVIDER: S-EPMC8647530 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature